Gregory Renza
Stock Analyst at RBC Capital
(2.04)
# 2,800
Out of 4,826 analysts
198
Total ratings
32.07%
Success rate
-5.65%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $9.08 | +252.42% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $279.80 | +14.37% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $28.18 | +141.31% | 3 | Apr 29, 2025 | |
| ONC BeiGene | Reiterates: Outperform | $312 | $254.16 | +22.76% | 1 | Apr 28, 2025 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $16 → $15 | $2.42 | +521.12% | 6 | Mar 27, 2025 | |
| CRMD CorMedix | Reiterates: Outperform | $12 | $9.03 | +32.89% | 6 | Mar 26, 2025 | |
| VSTM Verastem | Maintains: Outperform | $16 → $14 | $7.02 | +99.57% | 10 | Mar 21, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Sector Perform | $6 → $5 | $1.86 | +169.54% | 10 | Mar 19, 2025 | |
| EXEL Exelixis | Maintains: Outperform | $38 → $40 | $39.84 | +0.40% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $179 → $178 | $118.21 | +50.58% | 13 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $10.94 | +146.91% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $20.50 | +197.56% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $25.72 | -30.02% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $5.24 | +816.91% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.39 | +318.41% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $4.98 | +101.01% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $13.13 | +257.96% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $21.73 | +56.47% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $30.03 | +89.84% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $5.69 | -29.70% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.46 | +338.40% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $10.74 | +216.57% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.58 | +347.55% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $15.18 | +71.28% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.42 | +463.38% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $4.85 | +3,611.34% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.75 | +4,471.43% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.05 | +2,757.14% | 3 | Jun 2, 2020 |
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $9.08
Upside: +252.42%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $279.80
Upside: +14.37%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $28.18
Upside: +141.31%
BeiGene
Apr 28, 2025
Reiterates: Outperform
Price Target: $312
Current: $254.16
Upside: +22.76%
Perspective Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $2.42
Upside: +521.12%
CorMedix
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $9.03
Upside: +32.89%
Verastem
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $7.02
Upside: +99.57%
Inovio Pharmaceuticals
Mar 19, 2025
Maintains: Sector Perform
Price Target: $6 → $5
Current: $1.86
Upside: +169.54%
Exelixis
Mar 13, 2025
Maintains: Outperform
Price Target: $38 → $40
Current: $39.84
Upside: +0.40%
Jazz Pharmaceuticals
Feb 26, 2025
Maintains: Outperform
Price Target: $179 → $178
Current: $118.21
Upside: +50.58%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.94
Upside: +146.91%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $20.50
Upside: +197.56%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $25.72
Upside: -30.02%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $5.24
Upside: +816.91%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.39
Upside: +318.41%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $4.98
Upside: +101.01%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $13.13
Upside: +257.96%
Dec 13, 2024
Initiates: Outperform
Price Target: $34
Current: $21.73
Upside: +56.47%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $30.03
Upside: +89.84%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $5.69
Upside: -29.70%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.46
Upside: +338.40%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $10.74
Upside: +216.57%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.58
Upside: +347.55%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $15.18
Upside: +71.28%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.42
Upside: +463.38%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $4.85
Upside: +3,611.34%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.75
Upside: +4,471.43%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.05
Upside: +2,757.14%